RAFAEL HOLDINGS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period
RAFAEL HOLDINGS, INC. (RFL) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period of 31.88 thousand shares for the 12-month period ending 2025-07-31, per its 10-K filed 2025-10-29.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod · last filed 2025-10-29
- RAFAEL HOLDINGS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2025-07-31 was 24.38K shares.
- RAFAEL HOLDINGS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2025-04-30 was 0.00 shares.
- RAFAEL HOLDINGS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2025-01-31 was 0.00 shares.
- RAFAEL HOLDINGS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2024-10-31 was 7.50K shares.
- RAFAEL HOLDINGS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2025 was 31.88K shares.
- RAFAEL HOLDINGS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2023 was 296.76K shares, a 68.54% decline from fiscal 2022.
- RAFAEL HOLDINGS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2022 was 943.30K shares, a 44840.69% increase from fiscal 2021.
- RAFAEL HOLDINGS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2021 was 2.10K shares, a 530.33% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 12 month |
|---|---|---|---|---|
| 2025-07-31 | 24.38K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-29 | 24.38K shares derived: sum of 2 quarters · filed 2025-10-29 | 24.38K shares derived: sum of 3 quarters · filed 2025-10-29 | 31.88K shares 10-K · filed 2025-10-29 |
| 2025-04-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-06-11 | 0.00 shares derived: sum of 2 quarters · filed 2025-06-11 | 7.50K shares 10-Q · filed 2025-06-11 | |
| 2025-01-31 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-03-14 | 7.50K shares 10-Q · filed 2025-03-14 | ||
| 2024-10-31 | 7.50K shares 10-Q · filed 2024-12-11 | |||
| 2023-07-31 | 375.00 shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-12-20 | 375.00 shares derived: sum of 2 quarters · filed 2024-12-20 | 296.76K shares 10-K/A · filed 2024-12-20 | |
| 2023-04-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-06-13 | 296.38K shares 10-Q · filed 2023-06-13 | ||
| 2023-01-31 | 296.38K shares 10-Q · filed 2023-03-14 | |||
| 2022-07-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-30 | 1.14K shares derived: sum of 2 quarters · filed 2023-10-30 | 915.02K shares derived: sum of 3 quarters · filed 2023-10-30 | 943.30K shares 10-K · filed 2023-10-30 |
| 2022-04-30 | 1.14K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-06-14 | 915.02K shares derived: sum of 2 quarters · filed 2022-06-14 | 943.30K shares 10-Q · filed 2022-06-14 | 943.30K shares derived: sum of 4 quarters · filed 2022-10-31 |
| 2022-01-31 | 913.88K shares derived: 10-Q 6 month − 10-Q/A 3 month · filed 2022-03-17 | 942.17K shares 10-Q · filed 2022-03-17 | 942.17K shares derived: sum of 3 quarters · filed 2022-10-31 | 942.17K shares derived: sum of 4 quarters · filed 2022-10-31 |
| 2021-10-31 | 28.29K shares 10-Q/A · filed 2022-02-28 | 28.29K shares derived: sum of 2 quarters · filed 2022-10-31 | 28.29K shares derived: sum of 3 quarters · filed 2022-10-31 | 28.29K shares derived: sum of 4 quarters · filed 2022-10-31 |
| 2021-07-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-10-31 | 0.00 shares derived: sum of 2 quarters · filed 2022-10-31 | 0.00 shares derived: sum of 3 quarters · filed 2022-10-31 | 2.10K shares 10-K · filed 2022-10-31 |
| 2021-04-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-06-14 | 0.00 shares derived: sum of 2 quarters · filed 2021-06-14 | 2.10K shares 10-Q · filed 2021-06-14 | |
| 2021-01-31 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-03-17 | 2.10K shares 10-Q · filed 2021-03-17 | ||
| 2020-10-31 | 2.10K shares 10-Q · filed 2020-12-15 | |||
| 2020-07-31 | 333.00 shares 10-K · filed 2021-10-18 | |||
| 2018-07-31 | 2.06K shares 10-K · filed 2018-10-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |